Prelude Therapeutics Inc
PRLD0.875USD
+0.047+5.66%
取引時間 （ET）15分遅れの株価
49.41M時価総額
損失額直近12ヶ月PER
詳細情報 Prelude Therapeutics Inc 企業名
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
企業情報
企業コードPRLD
会社名Prelude Therapeutics Inc
上場日Sep 25, 2020
最高経営責任者「CEO」Dr. Krishna (Kris) Vaddi, Ph.D.
従業員数131
証券種類Ordinary Share
決算期末Sep 25
本社所在地175 Innovation Boulevard
都市WILMINGTON
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号19805
電話番号13024671280
ウェブサイトhttps://preludetx.com/
企業コードPRLD
上場日Sep 25, 2020
最高経営責任者「CEO」Dr. Krishna (Kris) Vaddi, Ph.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
+29.33%
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+27.99%
Dr. Peggy A. Scherle, Ph.D.
Dr. Peggy A. Scherle, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
185.69K
+2.77%
Dr. Jane Huang, M.D.
Dr. Jane Huang, M.D.
President, Chief Medical Officer
President, Chief Medical Officer
90.27K
+7.15%
Ms. Mardi C. Dier
Ms. Mardi C. Dier
Independent Director
Independent Director
10.00K
--
Dr. Paul Scherer, M.D.
Dr. Paul Scherer, M.D.
Independent Director
Independent Director
--
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Independent Director
Independent Director
--
--
Mr. Bryant D. Lim, J.D.
Mr. Bryant D. Lim, J.D.
Chief Financial Officer, Chief Legal Officer, Corporate Secretary
Chief Financial Officer, Chief Legal Officer, Corporate Secretary
--
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
+29.33%
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+27.99%
Dr. Peggy A. Scherle, Ph.D.
Dr. Peggy A. Scherle, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
185.69K
+2.77%
Dr. Jane Huang, M.D.
Dr. Jane Huang, M.D.
President, Chief Medical Officer
President, Chief Medical Officer
90.27K
+7.15%
Ms. Mardi C. Dier
Ms. Mardi C. Dier
Independent Director
Independent Director
10.00K
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Sun, Jul 27
更新時刻: Sun, Jul 27
株主統計
種類
株主統計
株主統計
比率
OrbiMed Advisors, LLC
25.02%
Baker Bros. Advisors LP
23.20%
Vaddi (Krishna)
8.41%
Boxer Capital Management, LLC
4.83%
The Vanguard Group, Inc.
2.31%
Other
36.22%
株主統計
株主統計
比率
OrbiMed Advisors, LLC
25.02%
Baker Bros. Advisors LP
23.20%
Vaddi (Krishna)
8.41%
Boxer Capital Management, LLC
4.83%
The Vanguard Group, Inc.
2.31%
Other
36.22%
種類
株主統計
比率
Hedge Fund
31.09%
Private Equity
25.02%
Individual Investor
11.38%
Investment Advisor
9.38%
Investment Advisor/Hedge Fund
3.57%
Research Firm
0.70%
Venture Capital
0.06%
Bank and Trust
0.04%
Pension Fund
0.01%
Other
18.77%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
158
35.42M
81.22%
-13.38M
2025Q1
169
35.41M
81.20%
-13.64M
2024Q4
176
41.97M
99.49%
-4.74M
2024Q3
176
39.67M
94.09%
-11.21M
2024Q2
173
43.50M
103.37%
-2.47M
2024Q1
184
38.12M
90.60%
-8.41M
2023Q4
190
38.61M
71.39%
-9.45M
2023Q3
202
40.53M
76.60%
-4.90M
2023Q2
201
43.54M
105.11%
+2.58M
2023Q1
203
37.45M
102.57%
-2.14M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
OrbiMed Advisors, LLC
10.91M
25.02%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
10.12M
23.2%
-5.19K
-0.05%
Jun 12, 2025
Vaddi (Krishna)
3.67M
8.41%
+832.02K
+29.33%
Mar 31, 2025
Boxer Capital Management, LLC
2.11M
4.83%
+399.83K
+23.41%
Mar 31, 2025
The Vanguard Group, Inc.
1.01M
2.31%
-1.19K
-0.12%
Mar 31, 2025
T. Rowe Price Associates, Inc.
959.30K
2.2%
-53.05K
-5.24%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
919.00K
2.11%
-14.36K
-1.54%
Mar 31, 2025
Renaissance Technologies LLC
656.70K
1.51%
+22.20K
+3.50%
Mar 31, 2025
Acadian Asset Management LLC
529.33K
1.21%
+43.95K
+9.05%
Mar 31, 2025
Friedman (Paul A)
500.10K
1.15%
--
--
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
Dimensional US Core Equity 1 ETF
0%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
ProShares Ultra Nasdaq Biotechnology
0%
Schwab U.S. Small-Cap ETF
0%
Schwab U.S. Broad Market ETF
0%
iShares Micro-Cap ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
詳細を見る
Dimensional US Core Equity 1 ETF
比率0%
iShares Russell 2000 ETF
比率0%
Proshares Ultra Russell 2000
比率0%
ProShares UltraPro Russell2000
比率0%
ProShares Ultra Nasdaq Biotechnology
比率0%
Schwab U.S. Small-Cap ETF
比率0%
Schwab U.S. Broad Market ETF
比率0%
iShares Micro-Cap ETF
比率0%
Invesco Nasdaq Biotechnology ETF
比率0%
iShares Core S&P Total U.S. Stock Market ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
